# Phosphatidylcholine (LT-02) for Induction of Remission in Ulcerative Colitis

> **NCT02142725** · PHASE3 · TERMINATED · sponsor: **Dr. Falk Pharma GmbH** · enrollment: 468 (actual)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** LT-02
- **DRUG:** LT-02
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02142725
- **Lead sponsor:** Dr. Falk Pharma GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-07-21
- **Primary completion:** 2016-11-11
- **Final completion:** 2016-12-16
- **Target enrollment:** 468 (ACTUAL)
- **Why stopped:** IDMC recommendation
- **Last updated:** 2017-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02142725

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02142725, "Phosphatidylcholine (LT-02) for Induction of Remission in Ulcerative Colitis". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT02142725. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*